Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

Parakkal Deepak, William J. Sandborn

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations

Abstract

This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.

Original languageEnglish
Pages (from-to)603-626
Number of pages24
JournalGastroenterology Clinics of North America
Volume46
Issue number3
DOIs
StatePublished - Sep 2017

Keywords

  • Crohn's disease
  • Inflammatory bowel disease
  • Interleukin-12
  • Interleukin-12/23 monoclonal antibody
  • Interleukin-23
  • Ustekinumab

Fingerprint

Dive into the research topics of 'Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease'. Together they form a unique fingerprint.

Cite this